Yazen operates an online platform that pairs GLP-1 obesity medications with continuous digital care from a team of doctors, dietitians, psychologists, health coaches and physiotherapists. Active in Sweden, Norway, Denmark, the Netherlands, the United Kingdom, Germany and Spain, the company has treated more than 53,000 patients who have collectively lost over 640 tons. In 2025 Yazen’s revenue jumped 87 % to SEK 330 million, while gross profit doubled to roughly SEK 185 million, underscoring the scalability of its model. The clinic currently manages around 39,000 active patients and employs 290 staff, 220 of whom work clinically, including 130 licensed physicians. Yazen’s evidence-based approach has earned it the title “Weight Loss Treatment of the Year in Europe 2025” from Healthcare Business Review and recognition as the second fastest-growing startup in Europe by Sifted. With a newly secured credit facility, the company plans to accelerate international expansion and broaden access to its comprehensive obesity-care program.

Total raised

$32M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Feb 2026